CAMBRIDGE, Mass. and EXTON, Pa., Aug. 07, 2017 (GLOBE NEWSWIRE) -- ?Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2017.
Since April 1, 2017, the Company:
